ESMO-magnitude of clinical benefit scale version 1.1

PD-1 Blockade in Tumors with Mismatch-Repair Deficiency

Le, D. T., Uram, J. N., Wang, H., Bartlett, B. R., Kemberling, H., Eyring, A. D., Skora, A. D., Luber, B. S., Azad, N. S., Laheru, D., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1500596 · Cited by 9,377 · see citing works

Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer

Borghaei, H., Paz-Ares, L., Horn, L., Spigel, D. R., Steins, M., Ready, N. E., Chow, L. Q., Vokes, E. E., Felip, E., Holgado, E., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1507643 · Cited by 9,335 · see citing works

Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma

Larkin, J., Chiarion-Sileni, V., Gonzalez, R., Grob, J. J., Cowey, C. L., Lao, C. D., Schadendorf, D., Dummer, R., Smylie, M., Rutkowski, P., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1504030 · Cited by 8,157 · see citing works

Increased Survival in Pancreatic Cancer with nab-Paclitaxel plus Gemcitabine

Von Hoff, D. D., Ervin, T., Arena, F. P., Chiorean, E. G., Infante, J., Moore, M., Seay, T., Tjulandin, S. A., Ma, W. W., Saleh, M. N., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1304369 · Cited by 6,712 · see citing works

Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial

Herbst, R. S., Baas, P., Kim, D.-W., Felip, E., Pérez-Gracia, J. L., Han, J.-Y., Molina, J., Kim, J.-H., Arvis, C. D., Ahn, M.-J., et al. (2016) · The Lancet · doi:10.1016/s0140-6736(15)01281-7 · Cited by 6,449 · see citing works

Ipilimumab plus Dacarbazine for Previously Untreated Metastatic Melanoma

Robert, C., Thomas, L., Bondarenko, I., O'Day, S., Weber, J., Garbe, C., Lebbe, C., Baurain, J.-F., Testori, A., Grob, J.-J., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1104621 · Cited by 4,496 · see citing works

Anaplastic Lymphoma Kinase Inhibition in Non–Small-Cell Lung Cancer

Kwak, E. L., Bang, Y., Camidge, D. R., Shaw, A. T., Solomon, B., Maki, R. G., Ou, S. I., Dezube, B. J., Janne, P. A., Costa, D. B., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1006448 · Cited by 4,442 · see citing works

Trastuzumab emtansine for HER2-positive advanced breast cancer

Verma, S., Miles, D., Gianni, L., Krop, I. E., Welslau, M., Baselga, J., Pegram, M., Oh, D.-Y., Diéras, V., Guardino, E., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1209124 · Cited by 3,834 · see citing works

Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial

Rosenberg, J. E., Hoffman-Censits, J., Powles, T., van der Heijden, M. S., Balar, A. V., Necchi, A., Dawson, N., O'Donnell, P. H., Balmanoukian, A., Loriot, Y., et al. (2016) · The Lancet · doi:10.1016/s0140-6736(16)00561-4 · Cited by 3,669 · see citing works

PD-1 Blockade with Nivolumab in Relapsed or Refractory Hodgkin's Lymphoma

Ansell, S. M., Lesokhin, A. M., Borrello, I., Halwani, A. S., Scott, E. C., Gutierrez, M. E., Schuster, S. J., Millenson, M. M., Cattry, D., Freeman, G. J., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1411087 · Cited by 3,564 · see citing works

Pertuzumab plus Trastuzumab plus Docetaxel for Metastatic Breast Cancer

Baselga, J., Cortés, J., Kim, S.-B., Im, S.-A., Hegg, R., Im, Y.-H., Roman, L., Pedrini, J. L., Pienkowski, T., Knott, A., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1113216 · Cited by 2,532 · see citing works

Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere): a randomised multicentre, open-label, phase 2 trial

Gianni, L., Pieńkowski, T., Im, Y., Roman, L., Tseng, L., Liu, M.-C., Lluch, A. M., Starosławska, E., de la Haba-Rodríguez, J., Im, S., et al. (2011) · The Lancet Oncology · doi:10.1016/s1470-2045(11)70336-9 · Cited by 2,393 · see citing works

MPDL3280A (anti-PD-L1) treatment leads to clinical activity in metastatic bladder cancer

Powles, T. B., Eder, J. P., Fine, G. D., Braiteh, F. S., Loriot, Y., Cruz, C., Joaquim Bellmunt, B., Burris, H. A., Petrylak, D. P., Teng, S.-L. M., et al. (2014) · Nature · doi:10.1038/nature13904 · Cited by 2,383 · see citing works

A Phase 3 Trial of Bevacizumab in Ovarian Cancer

Perren, T. J., Swart, A. M., Pfisterer, J., Ledermann, J. A., Pujade-Lauraine, É., Kristensen, G. B., Carey, M. S., Beale, P. J., Cervantes, A. M. R., Kurzeder, C., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1103799 · Cited by 2,181 · see citing works

Pertuzumab, Trastuzumab, and Docetaxel in HER2-Positive Metastatic Breast Cancer

Swain, S. M., Baselga, J., Kim, S.-B., Ro, J., Semiglazov, V., Campone, M., Ciruelos, E., Ferrero, J.-M., Schneeweiss, A., Heeson, S., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1413513 · Cited by 2,164 · see citing works

AZD9291 in EGFR Inhibitor–Resistant Non–Small-Cell Lung Cancer

Jänne, P. A., Yang, J. C.-H., Kim, D.-W., Planchard, D., Ohe, Y., Ramalingam, S. S., Ahn, M.-J., Kim, S.-W., Su, W.-C., Horn, L., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1411817 · Cited by 2,116 · see citing works

Crizotinib in <i>ROS1</i>-Rearranged Non–Small-Cell Lung Cancer

Shaw, A. T., Ou, S.-H. I., Bang, Y.-J., Camidge, D. R., Solomon, B. J., Salgia, R., Riely, G. J., Varella-Garcia, M., Shapiro, G. I., Costa, D. B., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1406766 · Cited by 1,964 · see citing works

Olaparib Maintenance Therapy in Platinum-Sensitive Relapsed Ovarian Cancer

Ledermann, J. A., Harter, P., Gourley, C., Friedlander, M. L., Vergote, I. B., Rustin, G. J. S., Scott, C. L., Meier, W., Shapira‐Frommer, R., Safra, T., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1105535 · Cited by 1,891 · see citing works

Safety and clinical activity of pembrolizumab for treatment of recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-012): an open-label, multicentre, phase 1b trial

Seiwert, T. Y., Burtness, B., Mehra, R., Weiss, J., Berger, R., Eder, J. P., Heath, K., McClanahan, T., Lunceford, J., Gause, C., et al. (2016) · The Lancet Oncology · doi:10.1016/s1470-2045(16)30066-3 · Cited by 1,745 · see citing works

Olaparib Monotherapy in Patients With Advanced Cancer and a Germline BRCA1/2 Mutation

Kaufman, B., Shapira‐Frommer, R., Schmutzler, R. K., Audeh, M. W., Friedlander, M. L., Balmañà, J., Mitchell, G., Fried, G., Stemmer, S. M., Hubert, A., et al. (2014) · Journal of Clinical Oncology · doi:10.1200/jco.2014.56.2728 · Cited by 1,707 · see citing works

Pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory melanoma (KEYNOTE-002): a randomised, controlled, phase 2 trial

Ribas, A., Puzanov, I. J., Dummer, R., Schadendorf, D., Hamid, O., Robert, C., Hodi, F. S., Schachter, J., Pavlick, A. C., Lewis, K. D., et al. (2015) · The Lancet Oncology · doi:10.1016/s1470-2045(15)00083-2 · Cited by 1,580 · see citing works

Ceritinib in <i>ALK</i> -Rearranged Non–Small-Cell Lung Cancer

Shaw, A. T., Kim, D.-W., Mehra, R., Tan, D. S. W., Felip, E., Chow, L. Q. M., Camidge, D. R., Vansteenkiste, J., Sharma, S., De Pas, T., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1311107 · Cited by 1,495 · see citing works

Olaparib maintenance therapy in patients with platinum-sensitive relapsed serous ovarian cancer: a preplanned retrospective analysis of outcomes by BRCA status in a randomised phase 2 trial

Ledermann, J. A., Harter, P., Gourley, C., Friedlander, M. L., Vergote, I. B., Rustin, G. J. S., Scott, C. L., Meier, W., Shapira‐Frommer, R., Safra, T., et al. (2014) · The Lancet Oncology · doi:10.1016/s1470-2045(14)70228-1 · Cited by 1,437 · see citing works

Ramucirumab plus docetaxel versus placebo plus docetaxel for second-line treatment of stage IV non-small-cell lung cancer after disease progression on platinum-based therapy (REVEL): a multicentre, double-blind, randomised phase 3 trial

Garon, E. B., Ciuleanu, T.-E., Arrieta, O., Prabhash, K., Syrigos, K. N., Goksel, T., Park, K., Gorbunova, V., Kowalyszyn, R. D., Pikiel, J., et al. (2014) · The Lancet · doi:10.1016/s0140-6736(14)60845-x · Cited by 1,309 · see citing works

Activity and safety of crizotinib in patients with ALK-positive non-small-cell lung cancer: updated results from a phase 1 study

Camidge, D. R., Bang, Y., Kwak, E. L., Iafrate, A. J., Varella‐Garcia, M., Fox, S. B., Riely, G. J., Solomon, B., Ou, S. I., Kim, D., et al. (2012) · The Lancet Oncology · doi:10.1016/s1470-2045(12)70344-3 · Cited by 1,267 · see citing works

Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA study): overall survival results from a randomised, double-blind, placebo-controlled, phase 3 study

Swain, S. M., Kim, S.-B., Cortés, J., Ro, J., Semiglazov, V., Campone, M., Ciruelos, E., Ferrero, J.-M., Schneeweiss, A., Knott, A., et al. (2013) · The Lancet Oncology · doi:10.1016/s1470-2045(13)70130-x · Cited by 1,006 · see citing works

Everolimus for Subependymal Giant-Cell Astrocytomas in Tuberous Sclerosis

Krueger, D. A., Caré, M. M., Holland, K. D., Agricola, K. D., Tudor, C., Mangeshkar, P., Wilson, K. A., Byars, A. W., Sahmoud, T., & Franz, D. N. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1001671 · Cited by 1,003 · see citing works

Ramucirumab versus Placebo in Combination with Second-Line FOLFIRI in Patients with Metastatic Colorectal Carcinoma That Progressed during or after First-Line Therapy with Bevacizumab, Oxaliplatin, and a Fluoropyrimidine (RAISE): A Randomised, Double-Blind, Multicentre, Phase 3 Study

Tabernero, J., Yoshino, T., Cohn, A. L., Obermannova, R., Bodoky, G., Garcia-Carbonero, R., Ciuleanu, T.-E., Portnoy, D. C., Van Cutsem, E., Grothey, A., et al. (2015) · The Lancet Oncology · doi:10.1016/s1470-2045(15)70127-0 · Cited by 952 · see citing works

5-year analysis of neoadjuvant pertuzumab and trastuzumab in patients with locally advanced, inflammatory, or early-stage HER2-positive breast cancer (NeoSphere): a multicentre, open-label, phase 2 randomised trial

Gianni, L., Pieńkowski, T., Im, Y., Tseng, L., Liu, M.-C., Lluch, A. M., Starosławska, E., de la Haba-Rodríguez, J., Im, S., Pedrini, J. L., et al. (2016) · The Lancet Oncology · doi:10.1016/s1470-2045(16)00163-7 · Cited by 894 · see citing works

A standardised, generic, validated approach to stratify the magnitude of clinical benefit that can be anticipated from anti-cancer therapies: the European Society for Medical Oncology Magnitude of Clinical Benefit Scale (ESMO-MCBS)

Cherny, N. I., Sullivan, R., Dafni, U., Kerst, J. M., Sobrero, A., Zielinski, C., de Vries, E. G. E., & Piccart, M. J. (2015) · Annals of Oncology · doi:10.1093/annonc/mdv249 · Cited by 818 · see citing works

Accountability for reasonableness

Daniels, N. (2000) · BMJ · doi:10.1136/bmj.321.7272.1300 · Cited by 729 · see citing works

Phase III Study of Concurrent Versus Sequential Thoracic Radiotherapy in Combination With Cisplatin and Etoposide for Limited-Stage Small-Cell Lung Cancer: Results of the Japan Clinical Oncology Group Study 9104

Takada, M., Fukuoka, M., Kawahara, M., Sugiura, T., Yokoyama, A., Yokota, S., Nishiwaki, Y., Watanabe, K., Noda, K., Tamura, T., et al. (2002) · Journal of Clinical Oncology · doi:10.1200/jco.2002.12.071 · Cited by 705 · see citing works

Imiquimod 5% cream for the treatment of superficial basal cell carcinoma: results from two phase III, randomized, vehicle-controlled studies

Geisse, J. K., Caro, I., Lindholm, J. S., Golitz, L. E., Stampone, P. A., & Owens, M. (2004) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2003.11.066 · Cited by 500 · see citing works

Necitumumab plus gemcitabine and cisplatin versus gemcitabine and cisplatin alone as first-line therapy in patients with stage IV squamous non-small-cell lung cancer (SQUIRE): an open-label, randomised, controlled phase 3 trial

Thatcher, N., Hirsch, F. R., Luft, A. V., Szczęsna, A., Ciuleanu, T., Dediu, M., Ramlau, R., Galiulin, R., Bálint, B., Losonczy, G., et al. (2015) · The Lancet Oncology · doi:10.1016/s1470-2045(15)00021-2 · Cited by 481 · see citing works

Five-Year Survival Rates for Treatment-Naive Patients With Advanced Melanoma Who Received Ipilimumab Plus Dacarbazine in a Phase III Trial

Maio, M., Grob, J., Aamdal, S., Bondarenko, I., Robert, C., Thomas, L., Garbe, C., Chiarion‐Sileni, V., Testori, A., Chen, T., et al. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2014.56.6018 · Cited by 480 · see citing works

Standard chemotherapy with or without bevacizumab in advanced ovarian cancer: quality-of-life outcomes from the International Collaboration on Ovarian Neoplasms (ICON7) phase 3 randomised trial

Stark, D., Nankivell, M. G., Pujade-Lauraine, É., Kristensen, G. B., Elit, L., Stockler, M. R., Hilpert, F., Cervantes, A. M. R., Brown, J. M., Lanceley, A., et al. (2013) · The Lancet Oncology · doi:10.1016/s1470-2045(12)70567-3 · Cited by 137 · see citing works

Patient-reported outcomes from EMILIA, a randomized phase 3 study of trastuzumab emtansine (T-DM1) versus capecitabine and lapatinib in human epidermal growth factor receptor 2-positive locally advanced or metastatic breast cancer

Welslau, M., Diéras, V., Sohn, J., Hurvitz, S. A., Lalla, D., Fang, L., Althaus, B., Guardino, E., & Miles, D. (2014) · Cancer · doi:10.1002/cncr.28465 · Cited by 126 · see citing works

Process is the point: justice and human rights: priority setting and fair deliberative process

Gruskin, S., & Daniels, N. (2008) · American Journal of Public Health · doi:10.2105/ajph.2007.123182 · Cited by 112 · see citing works

Do Contemporary Randomized Controlled Trials Meet ESMO Thresholds for Meaningful Clinical Benefit?

Paggio, J. C. D., Azariah, B., Sullivan, R., et al. (2016) · Annals of Oncology · doi:10.1093/annonc/mdw538 · Cited by 89 · see citing works

Health-related quality-of-life assessment in CLEOPATRA, a phase III study combining pertuzumab with trastuzumab and docetaxel in metastatic breast cancer

Cortés, J., Baselga, J. M., Im, Y., Im, S., Pivot, X. B., Ross, G. A., Clark, E., Knott, A., & Swain, S. M. (2013) · Annals of Oncology · doi:10.1093/annonc/mdt274 · Cited by 71 · see citing works

Correlation of EGFR-expression with safety and efficacy outcomes in SQUIRE: a randomized, multicenter, open-label, phase III study of gemcitabine–cisplatin plus necitumumab versus gemcitabine–cisplatin alone in the first-line treatment of patients with stage IV squamous non-small-cell lung cancer

Paz-Ares, L. G., Socinski, M. A., Shahidi, J., et al. (2016) · Annals of Oncology · doi:10.1093/annonc/mdw214 · Cited by 71 · see citing works

Quality of life during olaparib maintenance therapy in platinum-sensitive relapsed serous ovarian cancer

Ledermann, J. A., Harter, P., Gourley, C., Friedlander, M. L., Vergote, I. B., Rustin, G. J. S., Scott, C. L., Meier, W., Shapira‐Frommer, R., Safra, T., et al. (2016) · British Journal of Cancer · doi:10.1038/bjc.2016.348 · Cited by 58 · see citing works

Perils of the Pathologic Complete Response

Rose, B. S., Winer, E. P., & Mamon, H. J. (2016) · Journal of Clinical Oncology · doi:10.1200/jco.2016.68.1718 · Cited by 53 · see citing works

Utilisation of the ESMO-MCBS in practice of HTA

Wild, C., Grössmann, N., Bonanno, P. V., et al. (2016) · Annals of Oncology · doi:10.1093/annonc/mdw297 · Cited by 47 · see citing works

Nivolumab (nivo) vs docetaxel (doc) in patients (pts) with advanced NSCLC: CheckMate 017/057 2-y update and exploratory cytokine profile analyses.

Borghaei, H., Brahmer, J. R., Horn, L., et al. (2016) · Journal of Clinical Oncology · doi:10.1200/jco.2016.34.15_suppl.9025 · Cited by 41 · see citing works

The European Society for Medical Oncology Magnitude of Clinical Benefit Scale in daily practice: a single institution, real-life experience at the Medical University of Vienna

Kiesewetter, B., Raderer, M., Steger, G. G., Bartsch, R., Pirker, R., Zöchbauer‐Müller, S., Prager, G. W., Krainer, M., Preusser, M., Schmidinger, M., et al. (2016) · ESMO Open · doi:10.1136/esmoopen-2016-000066 · Cited by 21 · see citing works

The Esmo Magnitude of Clinical Benefit Scale for Novel Cancer Medicines — Correspondence with Prioritization Decisions In Updating the Israeli National List of Health Services

Hammerman, A., Greenberg‐Dotan, S., Feldhamer, I., et al. (2015) · Value in Health · doi:10.1016/j.jval.2015.09.117 · Cited by 3 · see citing works

5th ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 5)

Cardoso, F., Paluch-Shimon, S., Senkus, E., Curigliano, G., Aapro, M. S., André, F., Barrios, C. H., Bergh, J., Bhattacharyya, G. S., Biganzoli, L., et al. (2020) · Annals of Oncology · doi:10.1016/j.annonc.2020.09.010 · Cited by 1,369 · see citing works

Renal cell carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

Escudier, B., Porta, C., Schmidinger, M., Rioux-Leclercq, N., Bex, A., Khoo, V., Grünwald, V., Gillessen, S., & Horwich, A. (2019) · Annals of Oncology · doi:10.1093/annonc/mdz056 · Cited by 1,151 · see citing works

Soft tissue and visceral sarcomas: ESMO-EURACAN-GENTURIS Clinical Practice Guidelines for diagnosis, treatment and follow-up

Gronchi, A., Miah, A. B., Dei Tos, A. P., Abecassis, N., Bajpai, J., Bauer, S., Biagini, R., Bielack, S., Blay, J. Y., Bolle, S., et al. (2021) · Annals of Oncology · doi:10.1016/j.annonc.2021.07.006 · Cited by 1,115 · see citing works

Prostate cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

Parker, C., Castro, E., Fizazi, K., Heidenreich, A., Ost, P., Procopio, G., Tombal, B., & Gillessen, S. (2020) · Annals of Oncology · doi:10.1016/j.annonc.2020.06.011 · Cited by 977 · see citing works

Safety and patient-reported outcomes of atezolizumab, carboplatin, and etoposide in extensive-stage small-cell lung cancer (IMpower133): a randomized phase I/III trial

Mansfield, A. S., Każarnowicz, A., Karaseva, N., Sánchez, A., De Boer, R., Andric, Z., Reck, M., Atagi, S., Lee, J.-S., Garassino, M., et al. (2020) · Annals of Oncology · doi:10.1016/j.annonc.2019.10.021 · Cited by 193 · see citing works

Critical Appraisal of Guideline Recommendations on Systemic Therapies for Advanced Hepatocellular Carcinoma: A Review

Cappuyns, S., Corbett, V., Yarchoan, M., Finn, R. S., & Llovet, J. M. (2024) · JAMA Oncology · doi:10.1001/jamaoncol.2023.2677 · Cited by 167 · see citing works

Updated treatment recommendations for prostate cancer from the ESMO Clinical Practice Guideline considering treatment intensification and use of novel systemic agents

Fizazi, K., & Gillessen, S. (2023) · Annals of Oncology · doi:10.1016/j.annonc.2023.02.015 · Cited by 119 · see citing works

The Use of (Network) Meta-Analysis in Clinical Oncology

ter Veer, E., van Oijen, M. G. H., & van Laarhoven, H. W. M. (2019) · Frontiers in Oncology · doi:10.3389/fonc.2019.00822 · Cited by 83 · see citing works

A Systematic Review of the Effect of Cancer Treatment on Work Productivity of Patients and Caregivers

Kamal, K. M., Covvey, J. R., Dashputre, A., Ghosh, S., Shah, S., Bhosle, M., & Zacker, C. (2017) · Journal of Managed Care &amp; Specialty Pharmacy · doi:10.18553/jmcp.2017.23.2.136 · Cited by 82 · see citing works

DETERMINING QUALITY REQUIREMENTS AT THE UNIVERSITIES TO IMPROVE THE QUALITY OF EDUCATION

Mustafa, N. H., Kelesbayev, D., & Alibekova, Z. D. (2018) · The Journal of Economic Research & Business Administration · doi:10.26577/be-2018-2-2141

Susquehanna Chorale Spring Concert "Roots and Wings"

Hawkins, D. (2017)

Genentech taps Affimed’s antibodies

Cross, R. (2018) · C&EN Global Enterprise · doi:10.1021/cen-09635-buscon15

KOMPLIKASI REGIONAL ANESTESI PADA PEDIATRIK

Sari, D. (2023) · Jurnal Komplikasi Anestesi · doi:10.22146/jka.v5i1.7322

Enxerto livre de arteria epigastrica inferior: avaliacao hemodinamica e angiografica pre e pos-operatoria

Dib, A., Puig, L. B., Salvadori, D., et al. (1988) · Arquivos Brasileiros de Cardiologia